GDF15（生长分化因子 15），也称为巨噬细胞抑制细胞因子 1 (MIC-1)，是一种参与能量平衡和体重控制调节的循环蛋白。 GDF15 水平升高与癌症患者恶病质和生存率降低有关。通过激活 GFRAL（GDNF 家族受体 α 样）-RET（转染期间重排）信号通路，GDF15 可以诱导体重减轻，使其成为治疗恶病质的潜在靶点。目前，还没有批准专门针对GDF15用于癌症恶病质治疗的抗体药物。然而，人们已经努力开发针对这一新兴靶点的抗体疗法。在这项研究中，我们生成了一种针对 GDF15 的单克隆抗体 KY-NAb-GDF15，该抗体在 GDF15 刺激下可有效阻断 GFRAL 介导的下游信号传导。该抗体表现出强大的中和活性并表现出高结合特异性。重要的是，我们的研究结果表明，这种抗体有望缓解癌症引起的恶病质和减轻化疗引起的体重减轻，从而为控制癌症恶病质提供显着的治疗潜力。版权所有：© 2024 Xiong 等人。这是一篇根据知识共享署名许可条款分发的开放获取文章，允许在任何媒体上不受限制地使用、分发和复制，前提是注明原始作者和来源。

GDF15 (growth differentiation factor 15), also known as macrophage inhibitory cytokine 1 (MIC-1), is a circulating protein involved in the regulation of energy balance and weight control. Elevated levels of GDF15 have been associated with cachexia and reduced survival rates in cancer patients. Through the activation of the GFRAL (GDNF-family receptor α-like)-RET (Rearranged during Transfection) signaling pathway, GDF15 can induce weight loss, making it a potential target for treating cachexia. Currently, there are no approved antibody drugs specifically targeting GDF15 for cancer cachexia treatment. However, efforts have been made to develop antibody-based therapeutics against this emerging target. In this study, we generated a monoclonal antibody KY-NAb-GDF15 against GDF15 that effectively blocks downstream signaling mediated by GFRAL upon stimulation by GDF15. This antibody demonstrates robust neutralizing activity and exhibits high binding specificity. Importantly, our findings indicate that this antibody holds promise in alleviating cancer-induced cachexia and mitigating chemotherapy-induced weight loss, thereby offering significant therapeutic potential for managing cancer cachexia.Copyright: © 2024 Xiong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.